TGFB1 and cutaneous melanoma: Our observations in tumor-bearing mice and human cutaneous melanoma metastases suggest that anti-GARP:TGF-β1 mAbs could serve as an immunotherapeutic approach to inhibit TGF-β1-dependent immunosuppression by intra-tumoral Tregs in patients with cancer.